Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessJohnson & Johnson Updates Guidance After Kenvue Separation

Johnson & Johnson Updates Guidance After Kenvue Separation

Add to Favorite
Added to Favorite


Following the completion of the Kenvue separation, Johnson & Johnson (NYSE:JNJ) revised its financials and 2023 guidance. The Consumer Health business financial results will now be presented as discontinued operations, encompassing a gain of approximately $20 billion in Q3/23. The company disclosed a total sales figure of $42.41 billion for the first half of its fiscal year, with adjusted earnings per share amounting to $4.97.
JNJ’s updated guidance reveals expectations of adjusted operational sales growth of 6.7%, excluding the Consumer Health business. This contrasts with the earlier projection of 6.5% growth that included the Consumer Health business.
Post-Kenvue separation, operational sales are projected to range from $83.6 billion to $84.4 billion, marking a change from the previous estimate of $99.3 billion to $100.3 billion. Adjusted earnings per share have been revised to $10.05, down from the previous $10.75.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Boston Beer Shares Drop 3 percent on Lowered Full-Year Guidance

The Boston Beer Company (NYSE:SAM) reported third-quarter earnings that...

DexCom Shares Drop 2 percent as Slowing Revenue Growth Overshadows Q3 Earnings Beat

DexCom (NASDAQ:DXCM) reported better-than-expected third-quarter earnings, but a sharp...

Skechers Shares Rise 5 percent on Strong Q3 Earnings and Upgraded Outlook

Skechers USA (NYSE:SKX) saw its shares soar 5% intra-day...